Publications by authors named "Samuel Schwartzbein"
Article Synopsis
- Treatment persistence in patients with psoriatic arthritis (PsA) is crucial for achieving effective outcomes, and guselkumab, an interleukin-23 inhibitor, has shown high persistence rates in clinical trials.
- A study analyzed real-world data to compare the treatment persistence between patients using guselkumab and those receiving their first subcutaneous tumor necrosis factor inhibitor (TNFi) from July 2020 to March 2022.
- Results indicated that on-label persistence rates were assessed using statistical models to evaluate the effectiveness of both treatments, highlighting the need for further real-world evidence in comparing these therapies.
Background: High healthcare costs could arise from unmet needs. This study used random forest (RF) and regression methods to identify predictors of high costs from a US payer perspective in patients newly diagnosed with generalized myasthenia gravis (gMG).
Methods: Adults with gMG (first diagnosis = index) were selected from the IQVIA PharMetrics Plus database (2017-2021).